Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

45
5 Big Pharma Stocks Investors Love Right Now

2018-07-13 investorplace
Solid clinical results for Biogen (NASDAQ:BIIB) sent the stock up nearly 20% in a single day last week. That set the tone for a number of hot drug stock picks for July.
NKTR ACAD BIIB JUNO CRSP ABBV NYTAB PFE BMY

33
Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

2018-07-13 seekingalpha
Discussion: ResTORbio (TORC) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infection-lowering ability. The datasets were published in Science Translational Medicine. The study showed that RTB101 both as monotherapy as well as in combination with Novartis’s Afinitor (everolimus), showed statistically significant reduced rate of respiratory tract infections.
SNWW AST ACHV URGN CDXC OVID AUPH SNWV DRNA AKCA TORC AUP AST.WS OSIR AGN MRK IONS NVS ABBV RMD BMY ABBV

31
Oakmark Fund: Second Quarter 2018

2018-07-13 seekingalpha
Average Annual Total Returns (06/30/18) Since Inception (08/05/91) 12.84% 10–year 12.48% 5–year 13.07% 1–year 13.46% 3–month 2.13% Gross Expense Ratio as of 09/30/17 was 0.90% Net Expense Ratio as of 09/30/17 was 0.86%
MGM APC FB BMYMP AAL ADP MA NFLX HOG IT V AFL ADPVV AAPL HLT AEUA BMY

26
Where Did Major Pharma Short Sellers Go?

2018-07-12 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
PFZ TEVJF MRK TEVA TEVVF ABBV LLY 500680 PFE PFIZER ABBV BMY

4
Company Spotlight: Forty Seven

2018-07-11 seekingalpha
Forty Seven is well-positioned to continue advancing their anti-CD47 antibody, Hu5F9, towards a potential first-in-class checkpoint inhibitor targeting the innate immune system.
MRK SURF FTSV TRIL BMY

0
Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

2018-07-11 globenewswire
COPENHAGEN, Denmark, July 11, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer vaccine, CV301, and Bristol Myers Squibb's checkpoint inhibitor, nivolumab (OPDIVO®), for the treatment of patients with resectable hepatic-limited metastatic colorectal cancer (mCRC).
BVNKF BMYMP BMY BVNRY

53
Sector ETF Week In Review For The Week Of July 2-6

2018-07-08 seekingalpha
There's good and bad news here. The good news is that most sectors rose. In fact, only one sector (Energy) was down and its loss was marginal. But the bad news is that the strongest sectors were defensive. Healthcare rose the most, followed by utilities. The XLP (consumer staples) was the fourth strongest sector.
PM FB PG GILD GOOG CVS V T CL MRK GOOGL JNJ AAPL KO VZ CSCO MSFT INTC PFE BMY MO

19
Your Daily Pharma Scoop: Exelixis Publishes Positive Data, Stellar Trial Succeeds, Kalytera's Pre-IND Meet

2018-07-07 seekingalpha
Exelixis (EXEL) announced results from the Phase 3 clinical trial of Cabometyx (cabozantinib) in treatment-experienced patients with hepatocellular carcinoma (‘HCC). The results were published in the New England Journal of Medicine (‘NEJM). Median overall survival (‘OS) showed statistically significant improvement over placebo. OS for Cabometyx was 10.2 months while that for placebo was 8 months. Median progression-free survival (‘PFS) too showed significant improvement.
KALTF EXEL KLH PRNAF NURO ISRG K CLVS JNJ SBOT PRAN PBT BMY

223
Short Sellers Hike Bets in Major Pharma Stocks

2018-06-27 247wallst
Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
PFZ TEVJF MRK TEVA TEVVF ABBV LLY 500680 PFE PFIZER ABBV BMY

150
Your Daily Pharma Scoop: Heron Spikes, Ironwood Pharma Moves Ahead, Mesoblast Positive

2018-06-27 seekingalpha
The Daily Scoop is going to turn one year soon. Thank you for reading, commenting, and supporting our efforts. Please go to the end of this article to read an important announcement.
IRWD REGN INO RVNC PCRX INCY TROV TNDM SHPG MEOBF MRK SENS HAE MESO HRTX BMY

73
SANUWAVE Signs Joint Venture Partnership with Tarbaca for 3 Countries in Central America

2018-06-26 globenewswire
SUWANEE, GA, June 26, 2018 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB: SNWV) is excited to announce the execution of a binding term sheet for a Joint Venture (JV) with Tarbaca Lightning, the distribution company of Latin America Pharma Supply Inc. The JV will cover Costa Rica, Panama, and El Salvador. It is expected that the JV will receive their initial devices in the second half of 2018 and begin generating revenue shortly thereafter.
SNWW BMYMP SNWV BMY

55
Under Armour Is A Winner - Cramer's Lightning Round (6/20/18)

2018-06-21 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, June 20.
PFPT NVCR CGNX UAA PANW WTW CHGG CYBR UA FEYE EMR BMY ROK

7
3 Things In Biotech, June 18: Some More Good Heme News!

2018-06-19 seekingalpha
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription?
BMY

12
Week In Review: Mevion Medical Of Boston Closes $150 Million Financing From China Investors

2018-06-17 seekingalpha
Mevion Medical Systems, a Boston area maker of proton therapy machines, closed a $150 million financing led by YuanMing Capital with participation by other China-based private equity investors. Mevion said the financing provides the company with growth capital, clears existing debt and "optimizes" the shareholder structure. The company believes its proton systems offer a smaller footprint, lower operating costs and improved clinical performance for cancer care.
TTPH APS BMY WXXWY

123
AGTC Announces Expansion of Clinical and Regulatory Leadership Teams

2018-06-14 globenewswire
20+ Year Medical Affairs and Ophthalmology Veteran, Lanita C. Scott, M.D., Appointed as Vice President of Clinical Research and Medical Affairs
AGTC REGN BMYMP BMY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

45m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to BMY / Bristol-Myers Squibb Co. on message board site Silicon Investor.

BMY (bristol myers squibb) Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
CUSIP: 110122108